RF Acquisition III
RFAM · Nasdaq · AI/Tech
ACTION COMING
no date filedNothing required today
A deal cannot close without a shareholder vote, and that meeting is where you redeem. No proxy setting its date is on file.
Outer bound: the outside date, 17 November 2027 — a long-stop nobody can claim cash on.
Cash per share
Held for each public share, as last filed on 30 Jun.
Last close
2.2% below cash vs estimated NAV
Daily close · 9 Sept 2026
SpacBrain’s read
Floor not confirmed
No redemption window has closed — but no dated redemption election is on file for this name either, so we cannot show you a date to act by.
What we do have: no window has closed, and the deadline we compute for it runs to 17 November 2027 — our arithmetic off the IPO date and the charter term, not a date any filing we hold states. That deadline is not itself a window you can redeem into. The full chain of evidence is under Evidence.
Change on the last daily close+0.1% day
That is $0.15 below the $10.13 of cash held per share as last filed — though the right to claim that cash is not confirmed on file. Against our ESTIMATE of what the trust holds today — ~$10.21, the filed figure carried forward at the T-bill — the same price is 2.2% below the cash. That estimate is our arithmetic, not a filing.
In plain terms
- What it is
- A $100M SPAC from RF Acquisition (Tse Meng Ng), listed on Nasdaq in February 2026. Each unit put $10.00 into the shareholders' cash account at listing; it holds $10.13 a share today — interest earned on the account, plus any payments the sponsor made to extend the deadline, spread over the shares that never cashed out.
- What it's doing now
- It agreed in July 2026 to merge with HCC Healthcare Pte. Ltd., a healthcare services company. The deal values that business at about $500M. No date has been filed for the shareholder vote.
- What you should know
- We have no filed date on which you could claim the cash back, so we cannot tell you a day to act by. That is a gap in the public record, not a statement that the right has gone.
At a glance
- Where it stands
- Deal announced · next: the shareholder vote, awaiting filing
- A deal has been announced. Before anyone can redeem, a merger proxy has to be filed — an S-4 or F-4 registration statement, or a preliminary proxy — the SEC has to clear it, and a meeting date has to be set. That meeting is where you redeem. No such date is on file with us, so there is none to show.
- Merging with
- HCC Healthcare Pte. Ltd.
- Industry
- Health Care — healthcare services
- What it set out to buy: AI/Tech
- Deal value
- $500M
- announced 9 July 2026
- Price vs cash floor
- $9.98 vs $10.13
- $0.15 below the last filed cash held for you; 2.2% below cash against our estimated ~$10.21
- Cash left in trust
- $101.3M
- IPO
- 13 February 2026
- $100M raised · 100.0% of each $10 unit into trust
- Headquarters
- 111 SOMERSET ROAD, #05-07, SINGAPORE, 238164
- registered in the Cayman Islands
- Lead underwriter
- EarlyBirdCapital, Inc.
- Key officers
- Wen Ryan Lee (Director) · Shng Yunn Chinn (Director) · Ng Tse Meng (CEO and Chairman)
- Listed securities
- RFAM common · RFAM common $10.02 · RFAMU unit $10.02 · RFAMR right $0.11
As last filed, 30 June 2026.
source: XBRL companyfacts
Modelled, not filed: $10.13 filed 30 June 2026, compounded 72 days at the 3.95% 3-month T-bill (treasury.gov daily par yield curve). No tax drag, extension deposits or dissolution costs are modelled.
- vs last filed NAV
- 1.5%below cash
- $10.13, as of Jun 30, 2026
- vs estimated NAV today (our estimate)
- 2.2%below cash
- ~$10.21, accrued 72 days at 3.95%
Two denominators, one price. The filed figure is what a document says the trust held on its date; the estimate carries it forward at the T-bill for the days since, which is our arithmetic and not a filing.
A deal has been announced. Before anyone can redeem, a merger proxy has to be filed — an S-4 or F-4 registration statement, or a preliminary proxy — the SEC has to clear it, and a meeting date has to be set. That meeting is where you redeem. No such date is on file with us, so there is none to show. The outside date we hold is 17 November 2027 — a contractual long-stop, not a date you can claim cash on. What an outside date is →
Yield to redemption
No dated redemption window on file — no yield to compute.
We hold no redemption election for this SPAC. The only dated event on file is the outside date on Nov 17, 2027, which pays a holder nothing — so no yield can be measured to it. An unsourced date would make the yield look filed when it is not.
What is protecting this price
The reasoning behind the verdict above, in the order the filings establish it.
- No dated redemption election is on file for this name. That is an absence in the record, not proof that the right has gone — but it does mean this page cannot tell you a day to act by.
- Cash held in trust is $10.13 per share as last filed. That is the figure a redemption pays out at, plus whatever interest the trust earns between the filing and the window.
- The charter runs to a date no filing we hold states; from the IPO date and the charter term we estimate 17 November 2027. Whenever it falls, if no deal closes by then the trust is returned to holders — a floor of a different kind: it pays out, but you do not choose when, and this one you should read out of the prospectus yourself.
What has happened, and what is coming
3 dated milestonesEvery dated step from the day it listed to the next date you may have to act on. Where you have to do something, the day your broker needs the instruction is marked too.
- 13 February 2026IPOpassed
$100M raised into trust
- 9 July 2026Deal announcedpassed
Combination with HCC Healthcare Pte. Ltd.
- 17 November 2027Outside date
The deal
terms as filedWhat it is buying, on what terms, and how much of the combined company new shares take from you.
- HCC Healthcare Pte. Ltd.$500M · announced 9 July 2026announcedHealth CareSEC primary
HCC Healthcare Pte. Ltd. is a Singapore-incorporated exempt private company that operates through consolidated subsidiaries in Taiwan, forming one of the largest integrated medical and long-term care platforms on the island. The group traces its origins to a single obstetrics clinic founded by Dr. Hsiao Chung-Cheng, and over more than three decades of clinical heritage has evolved into a comprehensive healthcare ecosystem spanning Northern, Central, and Southern Taiwan. On a pro forma combined basis, the network encompasses more than 120 long-term care facilities and over 9,000 licensed beds, including one of the largest caregiving institutions in Taiwan with more than 1,300 beds, operated under a distinctive "hospital-within-an-eldercare-institution" ecosystem model. The group also provides community- and home-based case management for over 7,000 individuals, concentrated in Northern Taiwan, a region representing roughly one-third of the country's population. Its service offerings span medical care, long-term care, caregiver support, rehabilitation, hemodialysis, pharmaceutical services, infection control, nutritional support, social work, medical transportation, consumables procurement, and medical education and consulting.
The company is organized around four strategic business segments: a regional healthcare network anchored by Hsiao Chung-Cheng Hospital (a Grade A NHI-accredited facility), an AI technology platform, a smart long-term care and pharmacy chain operated through Fu Ze Health (a TriHealth subsidiary), and TriHealth Enterprise, which serves as the operational backbone for centralized procurement, logistics, and a long-term care transport fleet. HCC's AI platform leverages an exclusive partnership with Taiwan's National Center for High-Performance Computing for federated learning across all facilities, alongside robotic pharmacy dispensing, a real-time digital twin operational model, predictive analytics for chronic disease management, AI-powered clinical documentation, and a franchise engine designed for capital-efficient site rollouts. The group's strategic growth roadmap centers on four priorities: deploying its proprietary AI platform integrating spatial intelligence and multimodal clinical data, expanding into Japan leveraging existing infrastructure and Japan's regenerative medicine regulatory framework, developing cross-sector partnerships with fitness and wellness operators for preventive and chronic disease care pathways, and accelerating investment in precision and regenerative medicine including AI-driven biomarker profiling.
HCC Healthcare is led by Chief Executive Officer Jack Hsiao, while the SPAC side is headed by Tse Meng Ng, CEO of RF Acquisition Corp III, who also serves as Chief Advisor of DH Wealth Management and played a pivotal role in structuring and executing the transaction. The Singapore holding entity was formally incorporated on September 9, 2025, though the underlying operating group claims over five decades of healthcare heritage. The business combination with RF Acquisition Corp III (Nasdaq: RFAM) values HCC Healthcare at approximately US$500 million on a fully diluted equity basis, with a per-share reference value of US$10.00 following a pre-closing recapitalization. The deal is expected to close in the fourth quarter of 2026, subject to shareholder approvals, effectiveness of a Form F-4 registration statement, and Nasdaq or NYSE listing approval. Certain HCC shareholders and the SPAC founder Alfa 30 have signed voting support and lock-up agreements of up to six months post-closing, and the post-closing board will comprise seven directors, six from HCC and one from Alfa 30 Limited. EarlyBirdCapital is advising RF Acquisition, while K&L Gates and PricewaterhouseCoopers Legal are serving as U.S. and Taiwan counsel respectively to HCC Healthcare, with Bedrock Investment acting as strategic consultant to the company.
HCC Healthcare is pursuing a SPAC merger rather than a traditional
Deal structureSEC-primary — BCA 8-K / S-4 / DEFM14A$500Mvs$639M+28% dilutionEffective equity counts every claim on the post-close company at $10.00 — rollover, public shares, the founder promote and the PIPE. The headline counts only the target.
- Sponsor promote
- 28%
- Exchange ratio
1:1 plus rights. Each RFAC III ordinary share is cancelled and converted into one newly issued HCC Healthcare Ordinary Share; each RFAC III Right is exchanged for one-tenth (1/10th) of one Company Ordinary Share. HCC Healthcare shares are recapitalized to $10.00 per share off a $500,000,000 fully-diluted equity value.more ▾less ▴
PIPE structure:No committed PIPE at signing. The Business Combination Agreement (Section 9.7) only obliges the parties to use reasonable best efforts to obtain transaction financing of $75,000,000 in total, which mamore ▾less ▴
Outside date: the Closing has not occurred on or before the date falling 270 days after the date of this Agreement (the “ Agreement End Date ”), unless Acquiror is in material breach of this Agreement; — the contractual long-stop for closing. It is not a redemption deadline and confers no right to cash.
The score
deterministic, from filed fieldsOne number for the shape of the bet: how much upside you are getting per unit of downside. It is arithmetic over filed fields, not a rating and not advice — and it is the same number this SPAC carries on the leaderboard, the screener and the deal list, because all four read one engine.
1.5% below the last filed trust — floor not confirmed — no redemption election on file
The blend is trust discount (40 points), deal stage (30), sponsor track record (18) and time to catalyst (12). Every input is a real sourced field; where one is missing, confidence drops rather than a number being invented.
The company
from SEC filingsRead the full profile
RF Acquisition Corp III (Nasdaq: RFAM) is a Cayman Islands-incorporated blank-check company headquartered at 111 Somerset Road, #05-07, Singapore 238164, formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company operates as a generalist SPAC with no stated industry-specific focus. Its sponsor is Alfa 30 Limited, which acquired 3,833,333 founder shares for a total capital contribution of $25,000 on September 30, 2025. The management team is led by Chief Executive Officer and Director Tse Meng Ng and Chief Financial Officer and Director Chee Soon Tham, with additional directors Tuan Lee Low, Ryan Lee Wen, and Yunn Chinn Shng. EarlyBirdCapital, Inc. serves as the underwriter.
The company completed its initial public offering on February 13, 2026, raising $100 million through the sale of units on Nasdaq. Each unit was priced at $10.00 and contained one ordinary share and one-tenth of one right, with no warrants included in the unit structure. The trust account holds approximately $10.13 per share. The sponsor and EarlyBirdCapital agreed to purchase an aggregate of 350,000 private placement units at $10.00 per unit in a concurrent private placement. The company has 21 months from the closing of the IPO to consummate its initial business combination.
On 9 July 2026 the company announced a business combination with HCC Healthcare Pte. Ltd., a Singapore-incorporated company operating one of the larger integrated medical and long-term care groups in Taiwan through its subsidiaries, in a deal recorded at $500 million. Shareholders have not yet been asked to vote. The company's auditor is Marcum Asia CPAs LLP, and it is represented by legal counsel Winston Strawn LLP and Appleby (Cayman) Ltd.
Material findings
from the full read of every filingEvery document this company files gets read whole — body and exhibits. These are the ones the read flagged as material, newest first, each citing its filing.
This filing confirms the target and deal structure for investors tracking business combination progress, provides the trust account value per share ($10.13) and redemption mechanics, outlines sponsor conduct (founder share transfers, waivers), and notes the absence of any extension or adverse sponsor actions. The business combination agreement is a nonrecognized subsequent event, with closing conditions including shareholder approval and regulatory clearances.
This is the definitive deal announcement for RFAM. The trust per share is approximately $7.27 based on the stated trust amount and shares outstanding, which is below the $10.13 implied by the status, suggesting significant redemptions may have already occurred or the trust value has decreased. The deal values HCC at $500M. The Company funding extensions and transaction expenses reduces the cash available to the combined company. The 270-day deadline is tight for a Q4 2026 closing. The lock-up periods are standard but the sponsor's 6-month lock-up is typical. The business is a healthcare platform in Taiwan with a large long-term care network.
For redemption calendar watchers: The trust value per share is approximately $7.27, not $10.13 as previously indicated, which may affect redemption decisions. The 270-day outside date is well within the SPAC's 2027-11-17 deadline, reducing extension risk. The deal includes a $75 million financing target (PIPE or trust proceeds) and 3 million incentive shares reserved for non-redemption or PIPE investors. Sponsor conduct: Founder agreed to vote for the deal, not redeem, and lock up for six months—a positive signal. The target is a large healthcare platform in Taiwan with over 120 long-term care facilities and 9,000 beds, addressing a growing super-aged demographic. The filing contains extensive representations and warranties, conditions, and termination provisions (e.g., 45-day cure for company breach, 30-day for SPAC breach). Investors should monitor for SEC comment letters, shareholder vote timing, and any redemption statistics.
This filing is the first operational update post-IPO. The most material disclosure for investors is the entry into a non-binding LOI on March 17, 2026, confirming an active deal process. The trust value ($100.4M, ~$10.04/share) and the November 17, 2027, deadline are now confirmed. The filing also states management has concluded the Company has sufficient working capital, reducing near-term liquidity risk. The forfeiture of the over-allotment and the accretion of carrying value to redemption value are now quantified.
Establishes the initial trust value of $10.00 per share and the redemption deadline of November 17, 2027. Provides details on sponsor economics, including founder share forfeiture and valuation assumptions for EBC founder shares (23.6% probability of business combination). Confirms the SPAC has not yet identified a target. Important for shareholders monitoring redemption timelines and trust value.
The documented trust balance of $100,155,913 sets the precise redemption pool and liquidation ceiling for the 10,000,000 public shares, with the registrant noting redemptions will be paid at a pro-rata share of that amount plus accrued interest (net of taxes). The underwriters’ decision to forfeit the over-allotment permanently fixes the outstanding public unit count at 10,000,000 and reduces sponsor equity by 500,000 shares, altering post-merger ownership concentration without touching public trust capital. The 21-month deadline dictates the final redemption window; absent a shareholder-approved extension, the filing mandates the company cease operations, redeem 100% of public shares from the trust (less $100,000 for dissolution expenses), and liquidate. Per the registrant’s stated strategy, management holds broad discretion but intends to concentrate its acquisition search on businesses located in Asia within the deep technology sector, specifically citing artificial intelligence, quantum computing, and biotechnology. Exchange listing rules cited in the filing require the combined entity to acquire a target with a fair market value equal to at least 80% of the trust account assets (excluding released interest). Leadership is identified as Chief Executive Officer Tse Meng Ng, who executed the report, and audit oversight rests with Marcum Asia CPAs LLP, which issued an opinion on the February 17, 2026 balance sheet. The company discloses zero operating revenues, classifies itself as an emerging growth company electing not to opt out of the JOBS Act extended transition period, and acknowledges geopolitical and macroeconomic risks, including sanctions and supply chain disruptions stemming from the Russia-Ukraine conflict and the Israel-Hamas conflict, which could adversely affect target sourcing.
Show 10 more material filings
Investors monitoring the February 2026 reporting period receive no updated claims regarding target company pipelines, customer contracts, revenue projections, or financing structures. Because Director Lee Low Tuan’s filing records no equity movement, there is no fresh personnel or balance-sheet data to adjust extension voting likelihoods, liquidation risk models, or sponsor alignment assessments beyond the baseline tracking sheet.
This filing establishes the fundamental SPAC structure: trust value of $10.13 per share (per prompt metadata), redemption deadline, lock-up periods for founder shares (six months post-business combination) and private placement units (until business combination), and the contractual framework (voting agreements, trust waivers, expense reimbursement, and indemnification). The stated target focus on Asia deep tech provides investors with initial strategic direction. All subsequent de-SPAC activity will be measured against these baseline documents and the trust account mechanics.
A 25% founder promote (higher than the usual 20%) and a 21-month clock make this a tight, dilutive vehicle; the explicit Greater China exclusion narrows the target universe for an Asia deep-tech mandate, and the 15% redemption cap limits large holders' exit at the vote.
Beyond mechanics, the prospectus details the firm's strategic focus, governance tensions, and capital structure that shape investor risk. According to the filing, the management team will target Asia-based deep technology businesses in artificial intelligence, quantum computing, and biotechnology, while explicitly avoiding companies based in or operating primarily in Greater China.
The document specifies the exact tradable capital structure being listed: units comprising one ordinary share and one right; ordinary shares carrying a par value of $0.0001 per share; and rights entitling holders to receive one-tenth of one ordinary share upon completion of an initial business combination. Tse Meng Ng executed the filing as Chief Executive Officer on February 12, 2026. While procedurally routine for exchange listing compliance, it locks in the precise instruments governing SPAC liquidity, shareholder conversion rights, and post-deal equity distribution.
The disclosure maps the sponsor’s capital deployment and private placement mechanics directly to the trust account maintenance obligation, showing how initial shareholders and EBC will inject capital to sustain the stated $10.00 per unit trust benchmark during any over-allotment. The registrant notes that officers and directors have agreed to waive any right, title, interest, or claim in the trust account for services rendered, preserving trust balance integrity for redeeming public shareholders. The $190,000 miscellaneous expense allocation explicitly covers D&O insurance premiums until a business combination completes, indicating standard governance provisioning rather than commercial operation. Personnel updates show CEO Tse Meng Ng, CFO Chee Soon Tham, and directors Tuan Lee Low, Ryan Lee Wen, and Yunn Chinn Shng executed the filing. While the document does not modify the redemption deadline or the $10.13 trust-per-share metric cited in tracking databases, it provides a complete, audited-consent-backed ledger of issuer expenses, warrant/option-like private placement triggers, and indemnification boundaries under Cayman Islands law. No new business combination targets, revenue projections, or customer claims are presented, consistent with its status as a late-stage registration administration document.
The filing is significant because it provides the first detailed public disclosure of the SPAC's structure, sponsorship, and investment terms. It confirms the sponsor, Alfa 30 Limited (beneficially owned by CEO Tse Meng Ng), has a significant ownership stake (25%) acquired at $0.0065 per share, creating a conflict of interest where insiders have strong incentives to complete any deal, even if value-destructive, to avoid losing their investment. It also highlights a history of related-party transactions with prior SPACs (RF Acquisition Corp and RF Acquisition Corp II) by the same management team, which may present pre-existing fiduciary duties that could limit the pool of available targets. The filing's risk factors (e.g., no specified maximum redemption, potential for a shareholder vote to be avoided) are material for investors assessing redemption risk.
This filing is a step toward SEC declaring the IPO registration effective, enabling RF Acquisition Corp III to complete its initial public offering and begin its search for a business combination. It provides investors with the final terms of the offering, including trust size ($100M), redemption rights, sponsor compensation, and conflict disclosures. The trust value per share is $10.00, with a deadline of 21 months from closing (or 24 months if a proxy is filed within 21 months). No target business has been identified yet.
This filing confirms that RFAM is proceeding with its IPO on the same terms as originally proposed and has cleared an SEC comment cycle to the point of refiling exhibits. The appearance of comfort letters and legal opinions alongside the updated registration statement signals that the underwriter and counsel are prepared for the offering to go effective. For redemption-calendar trackers, the deadline remains 2027-11-17 (21 months from a presumed December 2025 IPO closing). For deal-progress monitoring, the sponsor’s prior SPAC track record (RF Acquisition Corp I completed with GCL Global; RF Acquisition Corp II signed with Nanyang Biologics) provides context but no new target. The ongoing working-capital deficit ($73,672 at 9/30/25) and audit going-concern paragraph underscore that the IPO cash is critical for survival.
This filing establishes the SPAC's baseline terms: trust redemption at $10.00 per share plus interest, no specified maximum redemption threshold, a 15%-of-shares cap on redemption if a shareholder vote is used, and a founder-share lock-up of six months post-business-combination. The exclusion of Greater China targets is an explicit constraint. The sponsor's prior SPAC track record (RF Acquisition Corp closed GCL Global in Feb 2025; RF Acquisition Corp II signed Nanyang Biologics in Oct 2025) provides deal-flow context but no guarantee of future results.
Filings
live EDGAR feedEverything this company has filed with the SEC recently, newest first, each with a plain summary of what changed and why it matters.
What changed: Amended Schedule 13G beneficial ownership report (SEC CIK [0001167557-26-000158]) submitted by AQR Capital Management, LLC, AQR Capital Management Holdings, LLC, and AQR Arbitrage, LLC. The filing updates a prior Section 13(d) disclosure. The provided excerpt omits adjusted share counts, ownership percentages, acquisition or disposition dates, and purpose statements, so the magnitude or direction of any beneficial ownership shift cannot be determined from the text alone. Why it matters: In a SPAC setting marked externally by a trust/share value of $10.13 and an extension deadline of 2027-11-17, amendments to institutional holdings can reflect portfolio rebalancing, arbitrage positioning, or changes in redemption liquidity expectations that may indirectly influence sponsor negotiation leverage and secondary trading volume. Because the document excerpt contains no percentage thresholds, transaction volumes, or intent declarations, it does not independently confirm alterations to the redemption timeline, trust liquidation mechanics, or sponsor conduct. The filing makes zero claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel; any substantive operational or financial assertions are entirely absent from this text.
What changed: Quarterly report on Form 10-Q for the period ended June 30, 2026, filed by RF Acquisition Corp III (RFAM), a blank-check company formed to pursue a business combination, with a focus on Asian deep-technology sectors. The Company reported that on July 9, 2026, it entered into a definitive Business Combination Agreement with HCC Healthcare Pte. Ltd., a Singapore healthcare company, valuing HCC Healthcare at $500 million on a fully-diluted basis ($10.00 per share). The transaction will convert each SPAC share into one HCC Healthcare share and each SPAC right into one-tenth of an HCC Healthcare share. The trust account held $101,273,496 as of June 30, 2026, equivalent to $10.13 per public share (10,000,000 shares). Sponsor Alfa 30 Limited transferred 900,000 founder shares to third-party designees. The Company also reported interest income on the trust of $870,264 for the quarter and $1,273,496 for the nine months. No material changes to risk factors were disclosed. Why it matters: This filing confirms the target and deal structure for investors tracking business combination progress, provides the trust account value per share ($10.13) and redemption mechanics, outlines sponsor conduct (founder share transfers, waivers), and notes the absence of any extension or adverse sponsor actions. The business combination agreement is a nonrecognized subsequent event, with closing conditions including shareholder approval and regulatory clearances.
What changed vs 2026-04-30trust $100.4M → $101.3M +1%trust account, sponsor loans outstanding, mandate language +11 moved · 3 with no prior record of ours
- Trust account
- $100.4M$101.3M
- Sponsor loans outstanding
- $150K · unchanged
- Mandate language
- The Company intends to pursue a Business Combination with a … · unchanged
- Redeemable shares
- 10.0M · unchanged
SpacBrain reads this as $870,264 was added to the trust between the two filings.
The clause “1,600 $ Prepaid expenses 53,948 30,900 Total Current Assets 945,548 30,900 Cash held in Trust Account 101,273,496 - Deferred offering costs - 82,594 Total Assets $ 102,219,044 $ 113,494 Liabilities, Ordinary Shares Subject to Possible”…
The clause …“Initial Public Offering. On February 25, 2026, the Company repaid the total outstanding balance of the promissory note amounting to $ 150,000 and the note is terminated. Due to Sponsor As of June 30, 2026, the balance of $ 46,071 due”…
The clause …“3,933,333 and 3,833,333 ordinary shares issued and outstanding (excluding 10,000,000 and 0 shares subject to possible redemption), respectively. As of September 30, 2025, the issued and outstanding ordinary shares include an”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Business Combination Agreement (BCA) filed as an 8-K, including merger agreement, support agreements, registration rights agreement, and press release. RF Acquisition Corp III entered into a definitive Business Combination Agreement with HCC Healthcare Pte. Ltd. on July 9, 2026. The merger consideration is one newly issued HCC ordinary share per RFAM ordinary share, and one-tenth of an HCC share per RFAM right. The pre-transaction equity value of HCC is $500M. The trust account had $101,273,495.71 as of June 30, 2026. The agreement includes a 270-day outside date (April 5, 2027). The Company will pay Acquiror's transaction expenses up to $7.5M and extension fees. The Founder (Alfa 30) agreed to a 6-month lock-up. HCC shareholders (Hsiao family) also agreed to a 6-month lock-up. Why it matters: This is the definitive deal announcement for RFAM. The trust per share is approximately $7.27 based on the stated trust amount and shares outstanding, which is below the $10.13 implied by the status, suggesting significant redemptions may have already occurred or the trust value has decreased. The deal values HCC at $500M. The Company funding extensions and transaction expenses reduces the cash available to the combined company. The 270-day deadline is tight for a Q4 2026 closing. The lock-up periods are standard but the sponsor's 6-month lock-up is typical. The business is a healthcare platform in Taiwan with a large long-term care network.
What changed: A Rule 425 written communication (Form 8-K) announcing the entry into a definitive Business Combination Agreement between RF Acquisition Corp III (RFAM) and HCC Healthcare Pte. Ltd., a Singapore healthcare company operating in Taiwan, along with full text of the merger agreement, voting and lock-up agreements, and a press release. This filing changes the SPAC's status from pre-deal to DEAL_ANNOUNCED. The definitive agreement sets a pre-transaction equity value of $500 million for HCC Healthcare, with each SPAC share converting into one new share of the combined company and each SPAC right converting into one-tenth of a share. The trust balance as of June 30, 2026 was at least $101,273,495.71, implying a per-share trust value of approximately $7.27 based on 13,933,333 shares outstanding. The SPAC's deadline is 2027-11-17, and the agreement has a 270-day outside date (April 5, 2027). The deal is subject to shareholder approval, SEC effectiveness, and Nasdaq listing. Founder (Alfa 30 Limited) and certain company shareholders agreed to six-month lock-ups post-closing. The transaction is expected to close in Q4 2026. Why it matters: For redemption calendar watchers: The trust value per share is approximately $7.27, not $10.13 as previously indicated, which may affect redemption decisions. The 270-day outside date is well within the SPAC's 2027-11-17 deadline, reducing extension risk. The deal includes a $75 million financing target (PIPE or trust proceeds) and 3 million incentive shares reserved for non-redemption or PIPE investors. Sponsor conduct: Founder agreed to vote for the deal, not redeem, and lock up for six months—a positive signal. The target is a large healthcare platform in Taiwan with over 120 long-term care facilities and 9,000 beds, addressing a growing super-aged demographic. The filing contains extensive representations and warranties, conditions, and termination provisions (e.g., 45-day cure for company breach, 30-day for SPAC breach). Investors should monitor for SEC comment letters, shareholder vote timing, and any redemption statistics.
What changed: A Schedule 13G beneficial ownership report submitted on May 13, 2026, by AQR Capital Management, LLC, AQR Capital Management Holdings, LLC, and AQR Arbitrage, LLC. According to the filing, the three named AQR-affiliated entities are reported as beneficial owners. The text enumerates no share quantities, acquisition or disposition dates, purchase prices, aggregate percentage thresholds, or source of funds. It contains no language addressing the November 17, 2027 redemption deadline, the $10.13 per-share trust account, any proposed business combination extension, merger approval timelines, or sponsor governance and compensation conduct. Why it matters: Because the submission discloses only entity names and lacks all operational and positional data, it does not recalibrate the mechanical parameters surrounding shareholder redemption windows or the stated $10.13 trust value. Routing through an arbitrage affiliate often reflects pre-close portfolio hedging, but without explicit position sizes, effective control assertions, or change-of-control triggers, the filing provides no actionable signal regarding liquidity demand, dilution math, or deal execution speed. Investors tracking the 2027 expiration horizon or potential proxy filings for an extension must look to subsequent 13D amendments, 424B prospectuses, or tender offer statements for material shifts in the timeline or trust calculus.
Show the other 10 filings
What changed: Quarterly report (Form 10-Q) for RF Acquisition Corp III for the quarter ended March 31, 2026, its second fiscal quarter. This is the Company's first 10-Q as a reporting public company following its IPO on February 17, 2026. The filing reports the IPO closing, private placement, and trust formation. Key incremental information: (a) On March 17, 2026, the Company entered into a non-binding letter of intent with a prospective target for a potential business combination. (b) Cash held in the Trust Account as of March 31, 2026, was $100,403,232, with a redemption value of $10.04 per share. (c) Net income for the six-month period was $673,033, driven by interest earned on the Trust Account ($403,232) and the change in fair value of the forfeited over-allotment liability ($422,000). (d) The Company reiterated its deadline of 21 months from the IPO closing (November 17, 2027) to complete an initial business combination. (e) The over-allotment option was forfeited on February 19, 2026. (f) The Company has $933,390 in cash outside the Trust Account to fund search and operations. Why it matters: This filing is the first operational update post-IPO. The most material disclosure for investors is the entry into a non-binding LOI on March 17, 2026, confirming an active deal process. The trust value ($100.4M, ~$10.04/share) and the November 17, 2027, deadline are now confirmed. The filing also states management has concluded the Company has sufficient working capital, reducing near-term liquidity risk. The forfeiture of the over-allotment and the accretion of carrying value to redemption value are now quantified.
trust account, redeemable shares, sponsor loans outstanding +1nothing moved · 4 with no prior record of ours
- Trust account
- not previously extracted$100.4M
- Redeemable shares
- not previously extracted10.0M
- Sponsor loans outstanding
- $150K · unchanged
- Mandate language
- The Company intends to pursue a Business Combination with a … · unchanged
The clause “390 $ Prepaid expenses 81,353 30,900 Total Current Assets 1,014,743 30,900 Cash held in Trust Account 100,403,232 - Deferred offering costs - 82,594 Total Assets $ 101,417,975 $ 113,494 Liabilities, Ordinary Shares Subject to Possible”…
The clause …“3,933,333 and 3,833,333 ordinary shares issued and outstanding (excluding 10,000,000 and 0 shares subject to possible redemption), respectively. As of September 30, 2025, the issued and outstanding ordinary shares include an”…
The clause …“Initial Public Offering. On February 25, 2026, the Company repaid the total outstanding balance of the promissory note amounting to $ 150,000 and the note is terminated. Due to Sponsor As of March 31, 2026, the balance of $ 16,071 due”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Form 10-Q quarterly report for the period ended December 31, 2025, prior to the SPAC's IPO completion, filed after the IPO but reflecting pre-IPO financials. This is the first 10-Q since inception. The balance sheet as of December 31, 2025 shows no cash, deferred offering costs of $758,705, a working capital deficit of $299,606, and a promissory note from the sponsor of $98,688. The IPO closed on February 17, 2026 (after quarter-end), placing $100,000,000 in the trust account ($10.00 per share) and raising $3,500,000 from a private placement. The underwriters' over-allotment option was forfeited, resulting in the cancellation of 500,000 founder shares. The combination period is 21 months from the IPO closing, or November 17, 2027. No business combination has been announced. Why it matters: Establishes the initial trust value of $10.00 per share and the redemption deadline of November 17, 2027. Provides details on sponsor economics, including founder share forfeiture and valuation assumptions for EBC founder shares (23.6% probability of business combination). Confirms the SPAC has not yet identified a target. Important for shareholders monitoring redemption timelines and trust value.
What changed: Form 8-K current report disclosing the consummation of an initial public offering, a concurrent private placement, the subsequent forfeiture of an underwriters’ over-allotment option, and accompanying audited financial statements and exhibits. According to the filing, RF Acquisition Corp III completed its initial public offering on February 17, 2026, selling 10,000,000 units at $10.00 per unit, generating gross proceeds of $100,000,000. Simultaneously, the company closed a private placement of 350,000 units at $10.00 per unit for $3,500,000; the registrant states these were purchased by sponsor Alfa 30 Limited and its designees (250,000 units) and underwriter EarlyBirdCapital, Inc., acting as representative (100,000 units). The audited balance sheet dated February 17, 2026, shows $100,155,913 deposited in the trust account, which management attributes to an over-funding of $155,913 wired by the sponsor. On February 19, 2026, the underwriters notified the company they would not exercise their 45-day over-allotment option to purchase up to 1,500,000 additional units, triggering the forfeiture of 500,000 founder shares originally issued to the sponsor. The filing details $4,708,386 in total transaction costs, including a $2,000,000 cash underwriting fee, $501,500 representing the fair value of 250,000 shares issued to EarlyBirdCapital, and $1,747,800 tied to 900,000 founder shares transferred to third-party designees. The sponsor recorded a $150,000 promissory note due at IPO closing and contracted to pay the sponsor a fixed administration fee of $10,000 per month for office space, utilities, and secretarial support beginning February 12, 2026. The registrant established a 21-month Combination Period from the IPO closing date to consummate an initial business combination. Why it matters: The documented trust balance of $100,155,913 sets the precise redemption pool and liquidation ceiling for the 10,000,000 public shares, with the registrant noting redemptions will be paid at a pro-rata share of that amount plus accrued interest (net of taxes). The underwriters’ decision to forfeit the over-allotment permanently fixes the outstanding public unit count at 10,000,000 and reduces sponsor equity by 500,000 shares, altering post-merger ownership concentration without touching public trust capital. The 21-month deadline dictates the final redemption window; absent a shareholder-approved extension, the filing mandates the company cease operations, redeem 100% of public shares from the trust (less $100,000 for dissolution expenses), and liquidate. Per the registrant’s stated strategy, management holds broad discretion but intends to concentrate its acquisition search on businesses located in Asia within the deep technology sector, specifically citing artificial intelligence, quantum computing, and biotechnology. Exchange listing rules cited in the filing require the combined entity to acquire a target with a fair market value equal to at least 80% of the trust account assets (excluding released interest). Leadership is identified as Chief Executive Officer Tse Meng Ng, who executed the report, and audit oversight rests with Marcum Asia CPAs LLP, which issued an opinion on the February 17, 2026 balance sheet. The company discloses zero operating revenues, classifies itself as an emerging growth company electing not to opt out of the JOBS Act extended transition period, and acknowledges geopolitical and macroeconomic risks, including sanctions and supply chain disruptions stemming from the Russia-Ukraine conflict and the Israel-Hamas conflict, which could adversely affect target sourcing.
What changed: A Form 8-K current report (Items 8.01 Other Events; Item 9.01 Financial Statements and Exhibits) accompanied by Exhibit 99.1, a corporate press release announcing the elective decoupling of listed securities. Per the press release signed by Chairman and CEO Tse Meng Ng, starting February 26, 2026, holders of the 10,000,000 units sold in the initial public offering may elect to separate the underlying ordinary shares (ticker RFAM) and rights (ticker RFAMR), where each right entitles the holder to one-tenth of one ordinary share upon an initial business combination. Unseparated units continue trading as RFAMU. Separation requires broker coordination with transfer agent Continental Stock Transfer & Trust Company. EarlyBirdCapital, Inc. acted as the sole book-running manager, and the registration statement became effective January 30, 2026. This procedural milestone does not modify the November 17, 2027 liquidation deadline, the $10.13 per-share trust balance, or any existing merger negotiations. Why it matters: Separate trading provides immediate liquidity for shareholders to manage risk exposure without triggering redemptions or altering trust mechanics. It confirms post-IPO clearing and tracking systems are operational ahead of the 2027 deadline and verifies standard underwriting and transfer-agent logistics are functioning. According to the 'About RF Acquisition Corp III' portion of the press release, management plans to target Asian deep technology firms (artificial intelligence, quantum computing, biotechnology) but expressly excludes companies based in or deriving most operations from Greater China. These strategic boundaries establish the addressable market scope for investors monitoring deal progression, while the mechanical update carries no force on the redemption calendar, valuation floor, or sponsor extension rights.
What changed: SEC Form 3 — initial statement of beneficial ownership, functioning here as a routine compliance exhibit. Alfa 30 Ltd, identified as a 10% owner, is reported to hold 4,083,333 shares directly. Because the filing records an initial ownership position rather than a trade or amendment, it does not alter the redemption deadline, adjust the trust account balance, trigger extension voting, or move merger negotiations forward. Why it matters: For investors monitoring capital structure and sponsor alignment, the report formally anchors Alfa 30 Ltd’s 4,083,333-share block as of 2026-02-23 without introducing derivative instruments or lock-up modifications. The document contains no operational or strategic claims: it references no customers, revenue targets, market sizing data, technology roadmaps, partnership agreements, litigation exposures, or personnel shifts. All assertions are sourced directly from the reporting party’s submission, and every numeric figure matches the text verbatim with no external computation or trust-convention imported.
What changed: FORM 3 — insider ownership report. Per the SEC submission, Ng Tse Meng (identified as director, CEO and Chairman, and 10% owner) maintains an indirect holding of 4,083,000 shares in RF Acquisition Corp III. The filing reports no acquisitions, dispositions, or derivative exercises. It makes no mention of alterations to the $10.13 per-share trust balance, the 2027-11-17 redemption deadline, any extension proposal, target acquisition progress, or sponsor conduct adjustments. Why it matters: Because the document exclusively catalogs a static equity position without accompanying transaction activity, it does not introduce secondary selling pressure that could affect share supply, voting thresholds, or trust distribution timelines. For investors monitoring the stated 2027-11-17 deadline and $10.13 trust value, this filing confirms those parameters remain undisturbed. Subsequent Form 4 filings or proxy materials will be required to disclose any actual trades, extension votes, or announced business combinations that could materially impact redemption decisions or sponsor alignment.
What changed: A SEC Form 3 routine compliance exhibit and initial insider ownership report, submitted on 2026-02-23, identifying reporting person Tham Chee Soon (director, Chief Financial Officer) of RF Acquisition Corp III. The filing states there are “No non-derivative transactions or holdings reported,” confirming no changes to insider equity positions, no impact on the $10.13 per share trust value, and no alteration to the 2027-11-17 redemption deadline or any deal announcement mechanics. Why it matters: For investors tracking redemption calendars, trust value, extensions, deal progress, and sponsor conduct, this document establishes a zero-activity regulatory baseline: no insider accumulation or liquidation that might signal private-side restructuring, liquidity demand, or confidence shifts ahead of the combination window. Beyond the officer titles and the explicit absence of reported transactions, it contains no substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, and therefore does not advance the SPAC’s transaction timeline or modify shareholder redemption rights.
What changed: A routine compliance exhibit — a Form 3 Statement of Changes of Beneficial Ownership filed under Section 16(a) of the Securities Exchange Act. The filing explicitly states no non-derivative transactions or holdings are reported for Wen Ryan Lee, director of RF Acquisition Corp III, meaning no change in insider equity allocation occurred that would affect public float composition, voting weight distributions, sponsor conduct obligations, extension negotiation leverage, trust account governance, or the mathematical backdrop for shareholder redemptions ahead of the calendar deadline. Why it matters: Investors tracking redemption mechanics, trust value preservation, and post-announcement deal execution will note that the document contains zero claims regarding customers, revenue streams, total addressable market sizing, strategic pivots, proprietary technology, commercial partnerships, active litigation, or additional executive appointments. Per the filing text, the sole content is the regulatory attestation of an unpopulated equity schedule, leaving capital structure dynamics, trust distribution waterfalls, and the execution timeline entirely unaffected by director-level trading activity.
What changed: SEC Form 3 insider ownership report. This Form 3 documents the initial or ongoing beneficial ownership disclosure for Director Shng Yunn Chinn in RF Acquisition Corp III, filed 2026-02-23 under SEC file number 0001829126-26-001591. The filer explicitly reports no non-derivative transactions or holdings. This notation leaves the SPAC’s trust value of $10.13 per share, its DEAL_ANNOUNCED status, and the 2027-11-17 deadline completely unchanged, with no adjustment to redemption mechanics, extension triggers, or sponsor capital positioning. Why it matters: For investors monitoring redemption timelines and sponsor alignment, this routine compliance snapshot confirms no reported insider share purchases or dispositions that would influence public float calculations or signal shifted confidence ahead of the 2027-11-17 deadline. The filing contains no substantive operational or financial assertions; there are no claimed details regarding customer pipelines, revenue trajectories, market sizing, commercial strategy, technology roadmaps, partnership structures, ongoing litigation, or executive personnel shifts attributed to the board or management team. Lacking transactional data or forward-looking statements, the Form 3 serves as a static regulatory baseline rather than a catalyst for trust recalibration or deal progression.
What changed: SEC Form 3 insider ownership report filed by RF Acquisition Corp III director Lee Low Tuan on 2026-02-23, identified by accession number 0001829126-26-001580. The report filed by Director Lee Low Tuan explicitly states 'No non-derivative transactions or holdings reported,' confirming zero changes to insider equity positions. Consequently, the stated trust value of $10.13 per share, the 2027-11-17 deadline, and the DEAL_ANNOUNCED status face no new insider buying, selling, or pledging activity that would signal a shift in sponsorship conduct or influence near-term redemption mechanics. Why it matters: Investors monitoring the February 2026 reporting period receive no updated claims regarding target company pipelines, customer contracts, revenue projections, or financing structures. Because Director Lee Low Tuan’s filing records no equity movement, there is no fresh personnel or balance-sheet data to adjust extension voting likelihoods, liquidation risk models, or sponsor alignment assessments beyond the baseline tracking sheet.
The sponsor
The people who set this company up, what they have done before, and the advisers around the deal.
Liquidation / termination drag: 0 liquidations and 0 terminations across 3 vehicles raised → 0% attrition (terminations 1.25×, stale shells 0.75×).
Mixed record · low confidence
- RF Acquisition Corp. · 2021→ GCL Global Holdings LtdGCLCompleted
RF Acquisition Corp II (RFAI) and III (RFAM) are sponsored by Alfa 24 Ltd and Alfa 30 Ltd — differently named sponsor vehicles, so the family rests on the people: four Section 16 filers are common to both, including officers Ng Tse Meng and Tham Chee Soon, who also served at RF Acquisition Corp. (RFAC).
Full sponsor record →Deal team — named in the prospectus
- EarlyBirdCapital, Inc.Lead-left
- I-Bankers Securities, Inc.Underwriter
Read from this SPAC’s own prospectus; the arrow opens the filing. Firms link to their full mandate record.
The record
The reference detail — how the shares were structured at listing, how thinly they trade, and where the company is registered.
Show the reference detail
Unit structure
That was the figure at listing. It is $10.13 a share today — interest on the account, plus any sponsor payments made to extend the deadline, spread over the shares that never cashed out. Unit: U = S + R/10 · 100.0% of the $10 unit
from 424B3 0001829126-26-001337
as of 10 September 2026
as of 10 September 2026
Trading & liquidity
Thin book — limit orders only; a position can be hard to exit outside a redemption window.
Company profile
Directors & officers
- Wen Ryan LeeDirector
- Shng Yunn ChinnDirector
- Ng Tse MengCEO and Chairman
- Lee Low TuanDirector
- Tham Chee SoonChief Financial Officer
Institutional holders
from SC 13G/13DFunds that have declared a stake above 5%. Heavy ownership by arbitrage funds usually means heavy cash-outs at the next vote.
Show the declared stakes
1 filer with a stake on file · 1 re-affirmed in the last 12 months. A stake with no amendment since is the filer’s last word on it, not proof it is still held — and percentages filed in different years are percentages of different floats, because this vehicle’s share count collapses at every redemption.
- AQR CAPITAL MANAGEMENT LLC4.3% · SC 13G/AAug 12, 2026 fresh
One line per filer, not per reporting person: a joint schedule names the management company, its funds and often the individual who controls them, and all of them report the same shares. Click a name for that filer’s whole footprint across every SPAC it has declared a stake in.
News
company wires and the financial pressReporting we have matched to this ticker. Headlines belong to the outlets that wrote them.
Show the headlines
- 3 Firms Guide Asian Healthcare Co.'s $500M SPAC Deal
Law360undated by the source
- united states securities and exchange commission
SEC EDGARundated by the source
- business combination agreement
SEC EDGARundated by the source
- HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Pursue Nasdaq Listing
Nasdaqundated by the source
- HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Pursue Nasdaq Listing
GlobeNewswireJul 9, 2026
6 social posts mention this ticker — unverified retail chatter, not reporting
- HCC Healthcare to go public via SPAC merger wit... — pluang.com
- HCC Healthcare signs deal to list on Nasdaq via SPAC merger — scanx.trade
- A proposed US$500 million deal is shining a spotlight ... — facebook.com
- SPAC Market Update July 10, 2026: RF Acquisition III ... — boardroomalpha.com
- RFAC III HCC Healthcare Merger: My Take on the Deal Structure — YouTube
- HCC HEALTHCARE PTE. LTD. — sg.ltddir.com
Sources on file
harvested pages, kept in fullEvery public page we have read about this company, stored in full so a source can never go missing.
Show the sources
35 full SEC filing texts archived — searchable, never lost.
- Vault note — RFAM (RF Acquisition III)
vault-note · /vault/tickers/RFAM
- Vault deal note — HCC Healthcare Pte. Ltd. (RFAM)
vault-note · /vault/deals/hcc-healthcare-pte-ltd
- RF Acquisition III to merge with HCC Healthcare | RFAM 8-K Filing
news · stocktitan.net
- RF Acquisition III to merge with HCC Healthcare | RFAM 8-K Filing
news · stocktitan.net
- HCC Healthcare signs SPAC deal for Nasdaq listing | RFAM Stock News
news · stocktitan.net
Listed peers
We hold no comparable set for this business — the target is Health Care — healthcare services. Comparables are selected from a dated vendor universe by business description, so an absent list means the description we hold matched nothing, not that no listed company is comparable.
In plain English
tap a term to open itEvery piece of jargon this page could have used, and what it actually means.
Open the plain-English guide
No floor / floorlessthe cash guarantee is gone — the price is unprotected
A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Broker action datethe day your broker needs the instruction — earlier than the official date
Brokers batch redemption instructions to the transfer agent, so the practical cutoff is roughly two business days before the published deadline. This is the date that actually costs people the floor.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Trust discountbuying below the cash held for you
Only meaningful while a redemption right exists. On a floorless name the same arithmetic is not a discount, it is the market pricing distress, and this product will not call it a yield.
Dilutionhow much of the company new shares take from you
Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.
Pro-forma equitywhat the company is valued at once the deal closes
The combined company's equity value assuming the announced terms and the redemptions that have actually happened.
ARShow much upside you get per unit of downside
SpacBrain's asymmetric-return score. It is deterministic — the same inputs always produce the same number — and it is capped, not zeroed, when the floor is gone.
De-SPACthe day the SPAC becomes the real company
The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.
Outside datethe contractual long-stop for closing the deal
A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.
Accreted NAV (estimate)the last filed cash figure, plus the interest it should have earned since
A model, not a filing: last filed value compounded at the 3-month T-bill for the days elapsed. Always shown in italic with the word estimate, and never printed beside a filed number without it.
Ask the brain
from its filingsData provenance & audit trail10 internal entries
Written by SpacBrain’s data agents whenever a figure is captured, corrected or flagged, and kept verbatim so every number on this page can be traced back to the filing that states it. This is a running log, not the current record: an early entry may be superseded by a later correction — the panels above always hold the current values.
deal activity detected (425 2026-07-09) — target TBD, verify
sponsor "Alfa 30 Ltd" (SEC CIK 0002110870) sourced from Form 3 reportingOwner (10% owner) acc 0001829126-26-001585.
linked to SponsorEntity "RF Acquisition (Tse Meng Ng)" (rf-acquisition-ng); sponsor of record "Alfa 30 Ltd".
rightShareRatio=0.1, unitSeparationDays=90 from the definitive prospectus (0001829126-26-001285). NOT FILLED: warrantStrike — no stated candidate; warrantCallPrice — no stated candidate
basis DERIVED: 2027-11-17 is OUR arithmetic — 2026-02-17 (IPO closing) + 21 months, re-derived here and equal to the stored value. 15 stored primary document(s) for CIK 0002091712 were read and none restates it as a calendar date, so no accession is stored: a citation beside our own arithmetic is the costume docs/METHODOLOGY.md §1.2b removes.
BCA signed 2026-07-09 (8-K acc 0001829126-26-007475, filed 7/10). Deal ACTIVE. Agreement End Date = 270 days after signing -> 2027-04-05 (BCA Ex 2.1 Sec 11.1(e)); also terminable if HCC shareholder approval not obtained within 35 business days after F-4 effectiveness. F-4 (to be filed by HCC Healthcare) NOT filed as of 2026-08-13 -> no meeting, no redemption deadline, no per-share $ stated. Charter deadline 2027-11-17 (21mo from 2/17/26 IPO close).
Primary-source deal structure (0001829126-26-007475, 0001829126-26-007711). effectiveEquityM left null: assumed refPrice $10.00; public shares counted pre-redemption — actual dilution falls with redemptions; promotePct unknown → founder promote excluded (effective equity understated) [bottom-up] FLAGS: Single share class: the 3,933,333 non-redeemable shares include founder + private placement + representative shares → promotePct is an upper bound | No PIPE, minimum-cash condition or termination fee disclosed in the BCA 8-K | F-4 (to be filed by HCC Healthcare) not filed as of 2026-08-13 → no pro-forma share count | no committed PIPE: the BCA only requires reasonable best efforts toward $75,000,000 of aggregate transaction financing (trust cash and/or a PIPE); no subscription agreement had been executed as of the BCA 8-K | no minimum cash condition: the Business Combination Agreement contains no 'Minimum Cash', 'Closing Cash' or 'Available Cash' condition; the $75,000,000 financing covenant is a best-efforts obligation, not a closing condition | no termination fee stated in the Business Combination Agreement or the BCA 8-K | no earnout disclosed | DB headline of $500M is confirmed by the BCA 8-K ($500,000,000 total equity value on a fully-diluted basis at $10.00 per share) | the IPO over-allotment option was forfeited by the underwriters on 2026-02-19, reducing the founder shares from 3,833,333 to 3,333,333; publicShares of 10,000,000 excludes the 600,000 Private Placement Units | no S-4/F-4 or proxy statement filed for this business combination as of 2026-08-14, so no pro-forma share table is available
OTHER -> HEALTHCARE, on 425 0001829126-26-007473: "HCC Healthcare Pte. Ltd., a Singapore private company limited by shares"
21 months from IPO closing 2026-02-17 -> 2027-11-17 (COMPUTED; 10-Q acc 0001829126-26-007711 states 21 months + closing date, no explicit end date printed). HCC Healthcare BCA Agreement End Date = 270 days after signing 2026-07-09 -> 2027-04-05 (BCA Ex 2.1, acc 0001829126-26-007475).